Trevi Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Trevi Therapeutics, Inc. (TRVI) reported Cash and Cash Equivalents, Period Increase (Decrease) of $64.19 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-12.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-12
- Trevi Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $58.44M.
- Trevi Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $5.74M.
- Trevi Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$8.90M.
- Trevi Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$6.06M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month |
|---|---|---|
| 2019-06-30 | $58.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $64.19M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $5.74M 10-Q · filed 2019-06-14 | |
| 2018-06-30 | -$8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$14.96M 10-Q · filed 2019-08-12 |
| 2018-03-31 | -$6.06M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |